Article Text

Download PDFPDF

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
  1. Nanhai Chen1,2,
  2. Mehmet Kilinc1,
  3. Qian Zhang1,2,
  4. Jason Aguilar1,
  5. Desislava Tsoneva5,
  6. Maysam Pessian3,
  7. Boris Minev1,3,4 and
  8. Aladar Szalay1,2,5
  1. Aff1 grid.466735.5Genelux Corporation San Diego CA USA
  2. Aff2 grid.266100.30000000121074242Radiation OncologyUCSD La Jolla CA USA
  3. Aff3 grid.266100.30000000121074242Moores Cancer CenterUCSD La Jolla CA USA
  4. Aff4 grid.266100.30000000121074242NeurosurgeryUCSD La Jolla CA USA
  5. Aff5 grid.8379.50000000119588658University of Wurzburg Wurzburg Germany

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Oncolytic viruses are a promising approach for cancer therapy. Recent clinical trials proved the safety and anti-tumor activity of several oncolytic viruses in solid tumors. However, very little is known about the potential of the oncolytic viruses to target hematologic malignancies. Careful analysis of the effects of the oncolytic viruses in patients with hematologic malignancies will lead to the development of more specific and effective treatment strategies.


We studied the abilities of various vaccinia-based oncolytic virus constructs to target and eliminate leukemic cells derived from patients with several hematologic malignancies. We used vaccinia virus constructs derived from the LIVP strain, LIVP 1.1.1. strain (plaque purified isolate of the nonattenuated LIVP strain), and from the WR strain. The ability of these constructs to infect and amplify in the patients’ leukemic cells and blast cells was studied with fluorescent microscopy, flow cytometry, and plaque assays for viral replication.


We found that our oncolytic virus constructs infected and killed the patient-derived leukemic cells. The LIVP 1.1.1.-based construct was the most efficient in infecting the leukemic cells, followed by the WR-based construct and the LIVP-based constructs. Flow cytometry data suggested that some of the infected cells have blast-like characteristics. Importantly, virus infection with the oncolytic vaccinia virus constructs correlated with the disease progression in these patients. In all experiments, the viral amplification and cytotoxicity were significantly higher in the leukemic cells than in the control healthy mononuclear cell subsets.


Our findings suggest the potential of our vaccinia-derived oncolytic virus constructs in targeting different hematologic malignancies. These findings are very relevant to the development of optimized clinical grade oncolytic vaccinia viruses for treatment of hematologic malignancies.